1. Home
  2. SPOK vs AVIR Comparison

SPOK vs AVIR Comparison

Compare SPOK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPOK
  • AVIR
  • Stock Information
  • Founded
  • SPOK 2004
  • AVIR 2012
  • Country
  • SPOK United States
  • AVIR United States
  • Employees
  • SPOK N/A
  • AVIR N/A
  • Industry
  • SPOK Telecommunications Equipment
  • AVIR Medicinal Chemicals and Botanical Products
  • Sector
  • SPOK Telecommunications
  • AVIR Health Care
  • Exchange
  • SPOK Nasdaq
  • AVIR Nasdaq
  • Market Cap
  • SPOK 318.9M
  • AVIR 273.0M
  • IPO Year
  • SPOK 1992
  • AVIR 2020
  • Fundamental
  • Price
  • SPOK $17.38
  • AVIR $3.73
  • Analyst Decision
  • SPOK Hold
  • AVIR Hold
  • Analyst Count
  • SPOK 1
  • AVIR 1
  • Target Price
  • SPOK $15.00
  • AVIR $6.00
  • AVG Volume (30 Days)
  • SPOK 118.0K
  • AVIR 398.9K
  • Earning Date
  • SPOK 07-23-2025
  • AVIR 08-06-2025
  • Dividend Yield
  • SPOK 7.17%
  • AVIR N/A
  • EPS Growth
  • SPOK N/A
  • AVIR N/A
  • EPS
  • SPOK 0.77
  • AVIR N/A
  • Revenue
  • SPOK $139,038,000.00
  • AVIR N/A
  • Revenue This Year
  • SPOK $2.26
  • AVIR N/A
  • Revenue Next Year
  • SPOK $2.54
  • AVIR N/A
  • P/E Ratio
  • SPOK $22.64
  • AVIR N/A
  • Revenue Growth
  • SPOK N/A
  • AVIR N/A
  • 52 Week Low
  • SPOK $13.55
  • AVIR $2.46
  • 52 Week High
  • SPOK $18.29
  • AVIR $4.15
  • Technical
  • Relative Strength Index (RSI)
  • SPOK 52.90
  • AVIR 74.60
  • Support Level
  • SPOK $17.33
  • AVIR $3.63
  • Resistance Level
  • SPOK $18.22
  • AVIR $3.78
  • Average True Range (ATR)
  • SPOK 0.43
  • AVIR 0.14
  • MACD
  • SPOK 0.01
  • AVIR 0.02
  • Stochastic Oscillator
  • SPOK 49.16
  • AVIR 100.00

About SPOK Spok Holdings Inc.

Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Share on Social Networks: